Accordingly, small molecule inhibitors of EGFR such as erlotinib (Tarceva) and gefitinib (Iressa) have been shown to attenuate glioma cell proliferation in vitro[5]–[7], although their clinical activity as single agents remains controversial due to the contradictory data obtained in clinical trials (reviewed in [8]). The gene discussed is EGFR; the disease is central nervous system cancer.